JP2020528936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528936A5 JP2020528936A5 JP2020527850A JP2020527850A JP2020528936A5 JP 2020528936 A5 JP2020528936 A5 JP 2020528936A5 JP 2020527850 A JP2020527850 A JP 2020527850A JP 2020527850 A JP2020527850 A JP 2020527850A JP 2020528936 A5 JP2020528936 A5 JP 2020528936A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023069335A JP7629651B2 (ja) | 2017-07-27 | 2023-04-20 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
| JP2025011548A JP2025066140A (ja) | 2017-07-27 | 2025-01-27 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537914P | 2017-07-27 | 2017-07-27 | |
| US62/537,914 | 2017-07-27 | ||
| PCT/US2018/043908 WO2019023460A1 (en) | 2017-07-27 | 2018-07-26 | ANTIBODIES AGAINST M (H) DM2 / 4 AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069335A Division JP7629651B2 (ja) | 2017-07-27 | 2023-04-20 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528936A JP2020528936A (ja) | 2020-10-01 |
| JP2020528936A5 true JP2020528936A5 (https=) | 2021-09-02 |
Family
ID=63165539
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527850A Withdrawn JP2020528936A (ja) | 2017-07-27 | 2018-07-26 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
| JP2023069335A Active JP7629651B2 (ja) | 2017-07-27 | 2023-04-20 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
| JP2025011548A Pending JP2025066140A (ja) | 2017-07-27 | 2025-01-27 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069335A Active JP7629651B2 (ja) | 2017-07-27 | 2023-04-20 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
| JP2025011548A Pending JP2025066140A (ja) | 2017-07-27 | 2025-01-27 | Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210032364A1 (https=) |
| EP (1) | EP3658178A1 (https=) |
| JP (3) | JP2020528936A (https=) |
| CN (1) | CN111491661B (https=) |
| AU (2) | AU2018306436A1 (https=) |
| CA (1) | CA3071105A1 (https=) |
| SG (1) | SG11202000634UA (https=) |
| WO (1) | WO2019023460A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220098328A1 (en) * | 2017-07-27 | 2022-03-31 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| SG11202000634UA (en) | 2017-07-27 | 2020-02-27 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| CA3127776A1 (en) * | 2019-01-30 | 2020-08-06 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| US20220153868A1 (en) * | 2019-02-20 | 2022-05-19 | Oncolyze, Inc | Hdm2 antibody for use in treating cancer |
| CN116082500B (zh) * | 2022-12-09 | 2023-08-22 | 珠海重链生物科技有限公司 | 抗SARS-CoV-2抗体nCoV1和nCoV2及其应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| CN118497136A (zh) * | 2024-06-06 | 2024-08-16 | 华中农业大学 | 一种高亲和力鼠抗乌鳢IgM单克隆抗体、杂交瘤细胞株及应用 |
| GB202413802D0 (en) * | 2024-09-19 | 2024-11-06 | Univ Court Univ Of Glasgow | MDM2 inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5411860A (en) | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| DE4345249C2 (de) | 1993-11-19 | 1997-12-11 | Deutsches Krebsforsch | hdm-2-Fragmente mit Bindungsregionen für hdm-2-spezifische Antikörper |
| US5770377A (en) * | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| FR2738151B1 (fr) | 1995-09-04 | 1997-09-26 | Rhone Poulenc Rorer Sa | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP2224961A1 (en) | 2007-11-26 | 2010-09-08 | The Research Foundation of the State University of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
| US8822419B2 (en) | 2008-10-03 | 2014-09-02 | The Research Foundation Of State University Of New York | Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells |
| CN102274186B (zh) * | 2010-06-11 | 2014-04-02 | 复旦大学 | 一种用于抗癌的镜像多肽脂质纳米制剂 |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| WO2013143026A1 (en) * | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| US9765117B2 (en) | 2015-08-24 | 2017-09-19 | Romek Figa | Peptides for treating cancer |
| SG11202000634UA (en) | 2017-07-27 | 2020-02-27 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| CA3127776A1 (en) | 2019-01-30 | 2020-08-06 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
-
2018
- 2018-07-26 SG SG11202000634UA patent/SG11202000634UA/en unknown
- 2018-07-26 AU AU2018306436A patent/AU2018306436A1/en not_active Abandoned
- 2018-07-26 CA CA3071105A patent/CA3071105A1/en active Pending
- 2018-07-26 WO PCT/US2018/043908 patent/WO2019023460A1/en not_active Ceased
- 2018-07-26 EP EP18752986.2A patent/EP3658178A1/en active Pending
- 2018-07-26 CN CN201880062611.5A patent/CN111491661B/zh active Active
- 2018-07-26 US US16/634,022 patent/US20210032364A1/en not_active Abandoned
- 2018-07-26 JP JP2020527850A patent/JP2020528936A/ja not_active Withdrawn
-
2021
- 2021-05-24 US US17/328,597 patent/US11407840B2/en active Active
-
2022
- 2022-07-25 US US17/814,596 patent/US20230295341A1/en not_active Abandoned
-
2023
- 2023-04-20 JP JP2023069335A patent/JP7629651B2/ja active Active
-
2025
- 2025-01-27 JP JP2025011548A patent/JP2025066140A/ja active Pending
- 2025-07-18 AU AU2025205612A patent/AU2025205612A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528936A5 (https=) | ||
| JP2023089245A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| RU2019116624A (ru) | Новые анти_cd137 антитела и их применение | |
| JP2019536470A5 (https=) | ||
| RU2019138067A (ru) | Биспецифическое антитело против ox40 и ctla-4 | |
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| US20240409632A1 (en) | Humanized antibodies against nectin-2 and drug conjugates thereof | |
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| JP2021520201A5 (https=) | ||
| JP2023037000A5 (https=) | ||
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| CN118103068A (zh) | 用抗ilt3抗体治疗急性髓系白血病的方法 | |
| JPWO2020081928A5 (https=) | ||
| US12202899B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| IL321677A (en) | Anti-PDL1 antibodies, multispecific antibodies, and methods of use | |
| JPWO2021092380A5 (https=) | ||
| US20260014268A1 (en) | Drug conjugates of humanized anti pvr antibodies | |
| US12612457B2 (en) | Humanized antibodies against Nectin-2 and drug conjugates thereof | |
| JPWO2020118295A5 (https=) | ||
| EP4590401A1 (en) | Humanized antibodies against nectin-4 and drug conjugates thereof | |
| JPWO2022263632A5 (https=) | ||
| JP2026514050A (ja) | 活性化可能な抗ｃｔｌａ４抗体をペンブロリズマブと組み合わせて使用いたがんの治療方法 | |
| RU2024119982A (ru) | Антитела к ox40, полиспецифические антитела и способы их применения | |
| RU2025100071A (ru) | Антитела против siglec15 и их применения |